Indication
Respiratory Infections
1 clinical trial
2 products
Product
RSP-1502Clinical trial
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung InfectionStatus: Recruiting, Estimated PCD: 2025-04-01